BioCentury
ARTICLE | Company News

AbbVie, Morphic partner on antifibrotic integrins

October 18, 2018 10:09 PM UTC

AbbVie Inc. (NYSE:ABBV) agreed to pay Morphic Therapeutic (Waltham, Mass.) $100 million up front for exclusive options to license antifibrotic integrins to block transforming growth factor (TGF) β activation via multiple undisclosed targets.

Morphic is responsible for R&D through IND-enabling studies for each potential product, at which point AbbVie may pay an undisclosed license fee to exercise its option to gain worldwide development and commercialization rights to that product...